New Approval in Early Breast Cancer: First Advance in 20 Years New Approval in Early Breast Cancer: First Advance in 20 Years

The CDK4/6 inhibitor abemaciclib (Verzenio) has been approved for use in early breast cancer for certain patients who are at high risk for recurrence.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news